A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Completed
BerGenBio AS
Phase 1/Phase 2
A Phase I/2 multi-center open-label study of BGB324 (bemcentinib) in combination with
erlotinib in participants with Stage IIIb or Stage IV non-small cell lung cancer. Bemcentinib
is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase
receptor which is connected with poor prognosis and acquired resistance to therapy.
A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Completed
BerGenBio ASA
Phase 1/Phase 2
A Phase I/2 multi-center open-label study of BGB324 (bemcentinib) in combination with
erlotinib in participants with Stage IIIb or Stage IV non-small cell lung cancer. Bemcentinib
is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase
receptor which is connected with poor prognosis and acquired resistance to therapy.
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
Active, not recruiting
BerGenBio AS
Phase 1/Phase 2
A Phase Ib/II multicentre open label study of bemcentinib (BGB324) as a single agent in
participants with Acute Myeloid Leukemia (AML) or Myelodysplastic syndrome (MDS) or in a
combination with cytarabine or decitabine in AML participants.
Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein
kinase receptor which is overexpressed in up to half of AML cases.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.